AVTX — Avalo Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534120 ·
Last close
$7.13
Market Cap
$412.28M
52W High
$24.27
52W Low
$6.53
ADV30
2,622,180
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -23,397,000 | -18,945,000 | 481,430,000 | 64,988,000 | 44,884,000 |
| Jun 2026 | 0 | — | -31,517,000 | -36,358,000 | 490,783,000 | 85,382,000 | 42,123,000 |
| Mar 2026 | 0 | — | -20,901,000 | -19,630,000 | 99,885,000 | 24,988,000 | 31,565,000 |
| Dec 2025 | 59,000 | 59,000 | -19,742,000 | -13,720,000 | 116,458,000 | 15,858,000 | 33,409,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,290,000
Investing CF
$-315,280,000
Financing CF
$426,664,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.92
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-504,510,000
Inventory
—
Receivables
—
ST Investments
$314,894,000
EBIT TTM
$-91,358,000
Pretax Income TTM
$-100,162,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,000
EBITDA
$-91,251,000
Free Cash Flow
$-23,271,000
Enterprise Value
$-20,869,978
Total Cash
$400,276,000
Total Debt
$242,000
Shares Out
57,823,083
Trailing EPS
$-2.26
Book Value
$4.49
ROE
-36.3%
ROA
-18.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 59,000 | -72,925,000 | -78,259,000 | 116,458,000 | 33,409,000 | 83,049,000 | -51,458,000 |
| Dec 2024 | 441,000 | -40,871,000 | -35,129,000 | 150,732,000 | 17,700,000 | 133,032,000 | -49,056,000 |
| Dec 2023 | 1,924,000 | -23,444,000 | -31,544,000 | 20,993,000 | 13,689,000 | 7,304,000 | -30,680,000 |
| Dec 2022 | 18,051,000 | -37,440,000 | -41,658,000 | 33,367,000 | 44,282,000 | -10,915,000 | -26,751,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$12,134,000
NetIncome TTM
$-100,333,000
OpCashFlow TTM
—
Assets (Latest)
$490,783,000
Forward EPS
$-2.58
Max Pain — expiry 2026-12-18
max pain strike: $7.50 · spot: $6.70 · call oi: 8,572 · put oi: 5,662
Expected Move to 2026-12-18:
±$1.55
(23.13%) —
implied range
$5.15 –
$8.25
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $417.01M | $7.51 | — |
| PTCHF | PureTech Health plc | $405.77M | $1.65 | — |
| OVID | Ovid Therapeutics Inc. | $418.98M | $2.22 | — |
| CTMX | CytomX Therapeutics, Inc. | $422.93M | $1.94 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $424.15M | $8.26 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
2026-11-11 20:15 · Yahoo
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
2026-11-05 12:00 · Yahoo
Avalo Therapeutics to Participate in Upcoming Investor Conferences
2026-11-02 21:00 · Yahoo
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-09-29 20:01 · Yahoo
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
2026-09-23 11:00 · Yahoo
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
2026-08-11 09:12 · Yahoo
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
2026-08-06 11:00 · Yahoo
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
2026-07-22 11:00 · Yahoo
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
2026-07-07 11:00 · Yahoo
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
2026-06-30 01:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.